




REVIEW

Parallel pathways in the biosynthesis of aminoglycoside antibiotics [version 1; referees: 2 approved]

Yi Yu¹, Qi Zhang², Zixin Deng ¹

¹Key Laboratory of Combinatorial Biosynthesis and Drug Discovery (Ministry of Education), School of Pharmaceutical Sciences, Wuhan University, 185 East Lake Road, Wuhan 430071, China

²Department of Chemistry, Fudan University, Shanghai 200433, China

v1 First published: 18 May 2017, 6(F1000 Faculty Rev):723 (doi: 10.12688/f1000research.11104.1)

Latest published: 18 May 2017, 6(F1000 Faculty Rev):723 (doi: 10.12688/f1000research.11104.1)

Abstract

Despite their inherent toxicity and the global spread of bacterial resistance, aminoglycosides (AGs), an old class of microbial drugs, remain a valuable component of the antibiotic arsenal. Recent studies have continued to reveal the fascinating biochemistry of AG biosynthesis and the rich potential in their pathway engineering. In particular, parallel pathways have been shown to be common and widespread in AG biosynthesis, highlighting nature's ingenuity in accessing diverse natural products from a limited set of genes. In this review, we discuss the parallel biosynthetic pathways of three representative AG antibiotics—kanamycin, gentamicin, and apramycin—as well as future directions towards the discovery and development of novel AGs.

Keywords

aminoglycoside, antibiotics, Resistance


Open Peer Review

Referee Status:  

| | Invited Referees | |
|--|---|---|
| | 1 | 2 |
| version 1 published 18 May 2017 |  |  |

F1000 Faculty Reviews are commissioned from members of the prestigious F1000 Faculty. In order to make these reviews as comprehensive and accessible as possible, peer review takes place before publication; the referees are listed below, but their reports are not formally published.

1 **Albert M. Berghuis**, McGill University, Canada

2 **Gong-Li Tang** , Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, China

Discuss this article

Comments (0)

Corresponding author: Zixin Deng (zxdeng@sjtu.edu.cn)

Competing interests: The authors declare that they have no competing interests.

Grant information: This work was funded by the National Natural Science Foundation of China (grants 31570033, 1500028, and 31670060); Q.Z. would also like to thank the Thousand Talents Program for support.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2017 Yu Y *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution Licence](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Yu Y, Zhang Q and Deng Z. **Parallel pathways in the biosynthesis of aminoglycoside antibiotics [version 1; referees: 2 approved]** *F1000Research* 2017, 6(F1000 Faculty Rev):723 (doi: [10.12688/f1000research.11104.1](https://doi.org/10.12688/f1000research.11104.1))

First published: 18 May 2017, 6(F1000 Faculty Rev):723 (doi: [10.12688/f1000research.11104.1](https://doi.org/10.12688/f1000research.11104.1))

Introduction

The discovery of streptomycin from *Streptomyces griseus* by Waksman in 1943 as a pharmaceutical legend against tuberculosis inspired massive mining of similar compounds in other bacterial species, leading to the discovery of neomycins, kanamycins, gentamicins, and a variety of other aminoglycoside (AG) antibiotics¹⁻⁴. Structurally, AGs possess a featured aminocyclitol core, usually as streptamine, streptidine, or 2-deoxystreptamine (2-DOS), which is decorated by one or more amino-sugars at the C4, C5, and C6 positions. These positively charged amino groups enable AGs to interact with negatively charged molecules, especially rRNAs of bacterial 30S and 50S ribosomal subunits, thereby inhibiting protein synthesis and causing cell death^{5,6}. Such a bactericidal property of AGs makes them broad-spectrum antibiotic agents that are effective against both Gram-negative and Gram-positive bacteria⁷. However, as has been observed for most antibiotics, heavy usage of AGs resulted in the rapid spread of AG-resistant pathogens, which has greatly limited their clinical practice⁸. The most common mechanism for bacterial resistance to AGs is inactivation of AGs by structural modifications⁹. Thus far, over 100 AG-modifying enzymes (AMEs), including AG N-acetyltransferases (AACs), AG O-nucleotidyltransferases (ANTs), and AG O-phosphotransferases (APHs), have been found in a broad range of both Gram-positive and -negative organisms¹⁰. Also, AG resistance can be achieved by efflux pumps and, as has been revealed recently, by 16S rRNA methyltransferase-catalyzed modifications¹¹. The bacterial resistance issues have been partly addressed by chemical modification of natural AGs to improve their pharmacological properties, as has been exemplified by the so-called second generation of AG drugs (the semisynthetic dibekacin, amikacin, netilmicin, and isepamicin) during the 1970s¹².

Whilst chemical engineering is an effective way to generate novel AGs, rational biosynthetic engineering of new antibiotics represents an attractive alternative, and the past decade has witnessed a massive upsurge of studies in AG biosynthesis^{13,14}. Among the largest and best-studied subgroup of AG natural products are the 2-DOS-containing AGs¹⁴. It has been well established that 2-DOS is produced from D-glucose-6-phosphate by a set of enzymes, including 2-deoxy-scyllo-inosose synthase, the dual-functional L-glutamine:2-DOI aminotransferase, and 2-deoxy-scyllo-inosamine dehydrogenase (the genes encoding these enzymes are conserved in all of the biosynthetic gene clusters identified so far for 2-DOS-containing AGs and are designated as “C, S, E”-type genes, respectively)^{7,15,16}. Decoration by various sugar moieties at the C4, C5, and C6 positions of 2-DOS proceeds via different patterns, yielding 4,5-disubstituted AGs (e.g. butirosin and neomycin), 4,6-disubstituted AGs (e.g. kanamycin, tobramycin, and gentamicin), or 4- and 5-monosubstituted AGs (e.g. apramycin and hygromycin). Readers are referred to many excellent reviews discussing the biosynthesis and engineering of AG antibiotics^{13-15,17,18}.

A common observation in AG biosynthesis is that one producer strain usually produces many AG congeners simultaneously. Recent studies have shown that the presence of multiple AG congeners is, in many cases, not merely because of inefficient downstream

modifications but mainly the result of parallel biosynthetic pathways¹⁹⁻²¹. This review discusses the recent advances in the biosynthesis of three representative AGs—kanamycin, gentamicin, and apramycin—which all involve parallel pathways. We attempt to highlight nature’s ingenuity in accessing diverse AGs through a limited set of genes and the potential for the generation of novel AG antibiotics by pathway engineering efforts.

Parallel pathways in kanamycin biosynthesis

The kanamycin class consists of several members, most of which were isolated from *Streptomyces kanamyceticus*¹. Structurally, these congeners contain the same kanosamine moiety (3-amino-3-deoxy-D-glucose) at the C6 position of 2-DOS but possess different amino-sugars at the C4 position of 2-DOS (i.e. 6-amino-6-deoxy-D-glucose in kanamycin A, neosamine in kanamycin B, and D-glucosamine in kanamycin C). Several second-generation AG drugs, such as amikacin, dibekacin, and arbekacin, are produced by semi-synthetic modification of the kanamycin core skeleton⁹, stimulating interest in deciphering kanamycin biosynthesis and developing novel kanamycin by bioengineering.

The parallel pathways of AG biosynthesis were firstly revealed for kanamycin²¹. For a long time, it had been postulated that kanamycin is assembled via a linear pathway⁷. However, the recent study by Yoon, Sohng, and co-workers indicated that kanamycin A and B are actually produced by two parallel pathways (Figure 1)²¹. KanF (also known as KanM1), the glycosyltransferase in the *kan* gene cluster, was shown to be able to transfer both NDP-glucose and NDP-N-acetylglucosamine to 2-DOS to generate 2'-hydroxy-paromamine and paromamine, respectively, thereby directing the metabolic flux of 2-DOS into two branches. The two resulting pseudodisaccharides are then aminated at the C6' position by the sequential action of a dehydrogenase KanQ (also known as KanI) and an aminotransferase KanB (also known as KacL), yielding 2'-hydroxyneamine and neamine, respectively. KanE (also known as KanM2), the second glycosyltransferase in the *kan* gene cluster, exhibits a very relaxed substrate promiscuity, accepting four different pseudodisaccharides (i.e. paromamine, neamine, 2'-hydroxyneamine, and 2'-hydroxy-paromamine) as glycosyl acceptors^{21,22}, resulting in the production of kanamycin A and B via the two independent pathways (Figure 1). The complex network of kanamycin biosynthesis is completed by the action of the α -ketoglutarate-dependent dioxygenase KanJ and the NADH-dependent reductase KanK, which together convert kanamycin B to kanamycin A²³. The remarkable substrate promiscuity of kanamycin biosynthetic enzymes suggests the great potential in AG combinatorial biosynthesis. Indeed, integration of the *S*-4-amino-2-hydroxybutyric acid (AHBA) biosynthesis genes into the kanamycin pathway successfully led to the production of a semisynthetic AG, amikacin, and a new AG analogue, 1-N-AHBA-kanamycin X, both of which show improved antibacterial activity compared with kanamycin A²¹.

Parallel pathways in gentamicin biosynthesis

Gentamicin was isolated from *Micromonospora echinospora* as a mixture of five C-series components consisting of C1, C2, C1a, C2a, C2b⁴. These compounds have received much attention in recent years as a broad-spectrum antibiotic for the treatment of




Figure 1. Parallel pathways in kanamycin biosynthesis. The 2-deoxystreptamine (2-DOS) moiety is highlighted in red, and the amino-sugar kanosamine (Kns) is highlighted in blue. GlcNAc, N-Acetylglucosamine.

various infections as well as a promising drug lead for the treatment of several inherited diseases and a sensitizing agent for lung cancer cells^{24–26}. Gentamicin contains the core 2-DOS moiety with the amino-sugars purpurosamine and garosamine attached at positions C4 and C6, respectively. The biosynthetic pathway for gentamicin was firstly proposed several decades ago, which is mostly corrected as shown by recent studies¹⁹. Heterologous expression of a subset of the gentamicin gene cluster in *Streptomyces venezuelae* indicated that gentamicin A2 is the first pseudotrisaccharide precursor of the gentamicin C complex²⁷. Gentamicin A2 is then converted to gentamicin X2 by a series of enzymes, including the dehydrogenase GenD2 and the pyridoxal phosphate (PLP)-dependent aminotransferase GenS2, the S-adenosylmethionine (SAM)-dependent N-methyltransferase GenN, and the radical SAM methyltransferase GenD1. GenD2 and GenS are responsible for the amination of the C3'' position of gentamicin A2, and the resulting amino group is methylated by GenN to afford a C3''

methylamino group²⁸. GenD1 belongs to the class B radical SAM methyltransferases^{29,30}, which utilizes a cobalamin cofactor and installs a methyl group on the C4'' position^{31,32}. Gentamicin X2 is then methylated at the C6' position by GenK, which, like GenD1, also belongs to the class B radical SAM methyltransferase, leading to the production of gentamicin G418³³.

Gentamicin G418 and X2 then serve as the starting substrates of the two parallel pathways and are first aminated at C6' by the sequential action of the dehydrogenase GenQ and the aminotransferase GenB1, resulting in gentamicin JI-20A and JI-20B, respectively¹⁹. Gentamicin JI-20A is then dideoxygenated by a set of uncharacterized enzymes (likely including a phosphotransferase, GenP) to produce gentamicin C1a, whose C6' amino group is then methylated by an as-yet-unknown methyltransferase to produce gentamicin C2b. Gentamicin JI-20B is also dideoxygenated and methylated to afford gentamicin C1. However, because of the

presence of several gentamicin congeners, including gentamicin JI-20Ba, gentamicin C2a, and gentamicin C2, and the involvement of the epimerase GenB2 that catalyzes the stereochemical inter-conversion of the C6' amino group, the exact reaction order and timing in gentamicin C1 production is currently unclear. A possible scenario is shown in Figure 2, in which GenB2 is responsible for the third parallel pathway and is not essential for gentamicin C biosynthesis; this hypothesis awaits testing in future studies. Unlike the parallel pathways in kanamycin biosynthesis, in which the final product of one pathway (kanamycin B) can be converted to the final product of the second one (kanamycin A), gentamicin C2b is the ultimate product and cannot be methylated by GenK to produce gentamicin C1. Clearly, many aspects in gentamicin biosynthesis remain elusive and warrant investigations.

Parallel pathways in apramycin biosynthesis

Apramycin is a highly modified AG containing a unique bicyclic octose moiety, which is deoxygenated at the C3 position. Although currently only licensed for veterinary practice use, apramycin represents the only known AG that is active against carbapenem-resistant Enterobacteriaceae isolates harboring the 16S rRNA MTases gene³⁴. In addition, apramycin is able to mimic the features of an incompatible plasmid, thereby re-sensitizing bacteria to conventional antibiotic treatments by causing plasmid loss

*in vivo*³⁵. More importantly, in contrast to common AGs that possess substantial ototoxicity and could cause irreversible hearing loss³⁶, recent studies have shown that apramycin has less ototoxicity, further promising its pharmaceutical applications³⁷.

The biosynthetic gene cluster of apramycin was reported more than a decade ago³⁸, but the biosynthetic timing of apramycin, particularly with regard to the C3 deoxygenation step, has remained obscure until very recently. In contrast to the previous proposal in which the C3 deoxygenation occurs as the penultimate step, biochemical studies have shown that the C3 deoxygenation is catalyzed by the radical SAM diol dehydratase AprD4 and its NADPH-dependent reductase partner AprD3^{20,39,40}. This C3 deoxygenation reaction does not occur on oxyapramycin but on the pseudodisaccharide substrate paromamine, demonstrating the two parallel biosynthetic pathways, which affords oxyapramycin and apramycin, respectively (Figure 3)²⁰. Consistent with this observation, biochemical analysis has shown that AprQ, a FAD-dependent dehydrogenase, catalyzes the C6' dehydrogenation of both paromamine and lividamine, with the latter as the preferred substrate²⁰. Remarkably, AprQ is also able to act on the tripseudodisaccharide substrate gentamicin X2 and G418 and, in the latter case, produce a novel gentamicin analogue with a C6' carboxylate²⁰. A similar observation was also made on AprD4




Figure 2. Parallel pathways in gentamicin biosynthesis. The 2-deoxystreptamine (2-DOS) moiety is highlighted in red.




Figure 3. Parallel pathways in apramycin biosynthesis. The 2-deoxystreptamine (2-DOS) moiety is highlighted in red.

and AprD3, which are able to act on tripeudodisaccharide substrates, such as kanamycin C and kanamycin B⁴⁰. The remarkable substrate promiscuity of apramycin biosynthetic enzymes demonstrates the great potential to produce novel AGs by pathway engineering efforts. It is also noteworthy that although the radical-mediated dehydration catalyzed by cobalamin-dependent diol dehydratase has been well studied, AprD4 represents the only known dehydratase in the radical SAM superfamily, and its catalytic mechanism remains to be determined.

Perspective

In 2015, Drs Youyou Tu, William Campbell, and Satoshi Ōmura jointly received the Nobel Prize in Physiology or Medicine for their seminal discoveries of the natural products avermectin and artemisinin, partly renewing interest in natural drug discovery and development. Despite their long history of clinical and veterinary usage, AGs still represent an important class of antibiotic for the treatment of severe infections, particularly for Gram-negative bacterial infections. Because of the recent global spread of AG-resistant pathogens and the inherent drawbacks of AGs such as ototoxicity and nephrotoxicity, the discovery and development of novel AGs is in urgent need^{41,42}. Mining of novel AGs from bacterial genomes is a promising way because of the rapid development of sequencing technology and the expansion of sequenced genomes that are publically available (<https://gold.jgi.doe.gov/>)⁴³. Pathway engineering serves as another attractive strategy to generate novel and more robust AGs¹⁸. The parallel biosynthetic pathways of AGs discussed above reflects nature's wisdom in structural diversity-oriented biosynthesis, highlighting the potential to access novel and more robust AGs by combinatorial biosynthesis while taking advantage of the substrate promiscuity of AG biosynthetic enzymes. Plazomicin is a new semisynthetic AG

designed to evade all clinically relevant AMEs and is currently under phase III clinical trials^{9,44}. It contains a gentamicin-related skeleton with a hydroxy-aminobutyric acid substituent and a hydroxyethyl substituent at its N-1' and N-6' positions, respectively⁴⁵. The promise of plazomicin to be approved as a third-generation AG drug and its structural similarity with gentamicin will undoubtedly spark increased interest in engineering AG pathways⁴⁶. Given that many aspects of AG biosynthesis remain unclear, further functional and mechanistic investigation of AG biosynthetic enzymes could be rewarding, which very likely entails novel and interesting biochemistries. With the expansion of our knowledge in AG biosynthesis and the availability of more and more synthetic biological tools, the resurgence of this old class of antibiotics is possible in the foreseeable future.

Abbreviations

AG, aminoglycoside; AHBA, S-4-amino-2-hydroxybutyric acid; AME, aminoglycoside-modifying enzyme; 2-DOS, 2-deoxystreptamine; SAM, S-adenosylmethionine.

Competing interests

The authors declare that they have no competing interests.

Grant information

This work was funded by the National Natural Science Foundation of China (grants 31570033, 1500028, and 31670060); Q.Z. would also like to thank the Thousand Talents Program for support.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References



1. Umezawa WA, Ueda M, Maeda K, *et al.*: **Production and isolation of a new antibiotic: kanamycin.** *J Antibiot (Tokyo)*. 1957; **10**(5): 181–8.
[PubMed Abstract](#)
2. Waksman SA: **Streptomycin: background, isolation, properties, and utilization.** *Science*. 1953; **118**(3062): 259–66.
[PubMed Abstract](#) | [Publisher Full Text](#)
3. Waksman SA, Lechevalier HA: **Neomycin, a New Antibiotic Active against Streptomycin-Resistant Bacteria, including Tuberculosis Organisms.** *Science*. 1949; **109**(2830): 305–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
4. Weinstein MJ, Luedemann GM, Oden EM, *et al.*: **Gentamicin, A New Antibiotic Complex From Micromonospora.** *J Med Chem*. 1963; **6**(4): 463–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
5. Carter AP, Clemons WM, Brodersen DE, *et al.*: **Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics.** *Nature*. 2000; **407**(6802): 340–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
6. Feldman MB, Terry DS, Altman RB, *et al.*: **Aminoglycoside activity observed on single pre-translocation ribosome complexes.** *Nat Chem Biol*. 2010; **6**(1): 54–62.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
7. Llewellyn NM, Spencer JB: **Biosynthesis of 2-deoxystreptamine-containing aminoglycoside antibiotics.** *Nat Prod Rep*. 2006; **23**(6): 864–74.
[PubMed Abstract](#) | [Publisher Full Text](#)
8. Magnet S, Blanchard JS: **Molecular insights into aminoglycoside action and resistance.** *Chem Rev*. 2005; **105**(2): 477–98.
[PubMed Abstract](#) | [Publisher Full Text](#)
9. Garneau-Tsodikova S, Labby KJ: **Mechanisms of Resistance to Aminoglycoside Antibiotics: Overview and Perspectives.** *Medchemcomm*. 2016; **7**(1): 11–27.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
10. Ramirez MS, Tolmasky ME: **Aminoglycoside modifying enzymes.** *Drug Resist Updat*. 2010; **13**(6): 151–71.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
11. Wilson DN: **Ribosome-targeting antibiotics and mechanisms of bacterial resistance.** *Nat Rev Microbiol*. 2014; **12**(1): 35–48.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
12. Becker B, Cooper MA: **Aminoglycoside antibiotics in the 21st century.** *ACS Chem Biol*. 2013; **8**(1): 105–15.
[PubMed Abstract](#) | [Publisher Full Text](#)
13. Kudo F, Eguchi T: **Aminoglycoside Antibiotics: New Insights into the Biosynthetic Machinery of Old Drugs.** *Chem Rec*. 2016; **16**(1): 4–18.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
14. Park SR, Park JW, Ban YH, *et al.*: **2-Deoxystreptamine-containing aminoglycoside antibiotics: recent advances in the characterization and manipulation of their biosynthetic pathways.** *Nat Prod Rep*. 2013; **30**(1): 11–20.
[PubMed Abstract](#) | [Publisher Full Text](#)
15. Kudo F, Eguchi T: **Biosynthetic genes for aminoglycoside antibiotics.** *J Antibiot (Tokyo)*. 2009; **62**(9): 471–81.
[PubMed Abstract](#) | [Publisher Full Text](#)
16. Piepersberg W, Aboshanab K, Schmidt-Beißner H, *et al.*: **The biochemistry and genetics of aminoglycoside producers.** *Aminoglycoside Antibiotics: From Chemical Biology to Drug Discovery* ed Arya, DP. 2007; 15–118.
[Publisher Full Text](#)
17. Flatt PM, Mahmud T: **Biosynthesis of aminocyclitol-aminoglycoside antibiotics and related compounds.** *Nat Prod Rep*. 2007; **24**(2): 358–92.
[PubMed Abstract](#) | [Publisher Full Text](#)
18. Park JW, Nam SJ, Yoon YJ: **Enabling techniques in the search for new antibiotics: Combinatorial biosynthesis of sugar-containing antibiotics.** *Biochem Pharmacol*. 2017; **134**: 56–73.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
19. Guo J, Huang F, Huang C, *et al.*: **Specificity and promiscuity at the branch point in gentamicin biosynthesis.** *Chem Biol*. 2014; **21**(5): 608–18.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
20. Lv M, Ji X, Zhao J, *et al.*: **Characterization of a C3 Deoxygenation Pathway Reveals a Key Branch Point in Aminoglycoside Biosynthesis.** *J Am Chem Soc*. 2016; **138**(20): 6427–35.
[PubMed Abstract](#) | [Publisher Full Text](#)
21. Park JW, Park SR, Nepal KK, *et al.*: **Discovery of parallel pathways of kanamycin biosynthesis allows antibiotic manipulation.** *Nat Chem Biol*. 2011; **7**(11): 843–52.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
22. Kudo F, Sucipto H, Eguchi T: **Enzymatic activity of a glycosyltransferase KanM2 encoded in the kanamycin biosynthetic gene cluster.** *J Antibiot (Tokyo)*. 2009; **62**(12): 707–10.
[PubMed Abstract](#) | [Publisher Full Text](#)
23. Sucipto H, Kudo F, Eguchi T: **The last step of kanamycin biosynthesis: unique deamination reaction catalyzed by the α -ketoglutarate-dependent nonheme iron dioxygenase KanJ and the NADPH-dependent reductase KanK.** *Angew Chem Int Ed Engl*. 2012; **51**(14): 3428–31.
[PubMed Abstract](#) | [Publisher Full Text](#)
24. Kobayashi M, Sone M, Umemura M, *et al.*: **Comparisons of cochleotoxicity among three gentamicin compounds following intratympanic application.** *Acta Otolaryngol*. 2008; **128**(3): 245–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
25. Linde L, Kerem B: **Introducing sense into nonsense in treatments of human genetic diseases.** *Trends Genet*. 2008; **24**(11): 552–63.
[PubMed Abstract](#) | [Publisher Full Text](#)
26. Cuccarese MF, Singh A, Amiji M, *et al.*: **A novel use of gentamicin in the ROS-mediated sensitization of NCI-H460 lung cancer cells to various anticancer agents.** *ACS Chem Biol*. 2013; **8**(12): 2771–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
27. Park JW, Hong JS, Parajuli N, *et al.*: **Genetic dissection of the biosynthetic route to gentamicin A, by heterologous expression of its minimal gene set.** *Proc Natl Acad Sci U S A*. 2008; **105**(24): 8399–404.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
28. Huang C, Huang F, Moison E, *et al.*: **Delineating the biosynthesis of gentamicin x2, the common precursor of the gentamicin C antibiotic complex.** *Chem Biol*. 2015; **22**(2): 251–61.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
29. Zhang Q, van der Donk WA, Liu W: **Radical-mediated enzymatic methylation: a tale of two SAMs.** *Acc Chem Res*. 2012; **45**(4): 555–64.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
30. Bauerle MR, Schwalm EL, Booker SJ: **Mechanistic diversity of radical S-adenosylmethionine (SAM)-dependent methylation.** *J Biol Chem*. 2015; **290**(7): 3995–4002.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
31. Ding W, Li Q, Jia Y, *et al.*: **Emerging Diversity of the Cobalamin-Dependent Methyltransferases Involving Radical-Based Mechanisms.** *ChemBiochem*. 2016; **17**(13): 1191–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
32. Zhou S, Alkhalaf LM, de Los Santos EL, *et al.*: **Mechanistic insights into class B radical-S-adenosylmethionine methylases: ubiquitous tailoring enzymes in natural product biosynthesis.** *Curr Opin Chem Biol*. 2016; **35**: 73–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
33. Kim HJ, McCarty RM, Ogasawara Y, *et al.*: **GenK-catalyzed C-6' methylation in the biosynthesis of gentamicin: isolation and characterization of a cobalamin-dependent radical SAM enzyme.** *J Am Chem Soc*. 2013; **135**(22): 8093–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
34. Livermore DM, Mushtaq S, Warner M, *et al.*: **Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates.** *J Antimicrob Chemother*. 2011; **66**(1): 48–53.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
35. Sezen B, Sames D: **Oxidative C-arylation of free (NH)-heterocycles via direct (sp³) C-H bond functionalization.** *J Am Chem Soc*. 2004; **126**(41): 13244–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
36. Jackson J, Chen C, Buisson K: **Aminoglycosides: how should we use them in the 21st century?** *Curr Opin Infect Dis*. 2013; **26**(6): 516–25.
[PubMed Abstract](#) | [Publisher Full Text](#)
37. Matt T, Ng CL, Lang K, *et al.*: **Dissociation of antibacterial activity and aminoglycoside ototoxicity in the 4-monosubstituted 2-deoxystreptamine apramycin.** *Proc Natl Acad Sci U S A*. 2012; **109**(27): 10984–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
38. Wehmeier UF, Piepersberg W: **Enzymology of aminoglycoside biosynthesis- deduction from gene clusters.** *Meth Enzymol*. 2009; **459**: 459–91.
[PubMed Abstract](#) | [Publisher Full Text](#)
39. Kim HJ, LeVieux J, Yeh YC, *et al.*: **C3'-Deoxygenation of Paromamine Catalyzed by a Radical S-Adenosylmethionine Enzyme: Characterization of the Enzyme AprD4 and Its Reductase Partner AprD3.** *Angew Chem Int Ed Engl*. 2016; **55**(11): 3724–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
40. Kudo F, Tokumitsu T, Eguchi T: **Substrate specificity of radical S-adenosyl-L-methionine dehydratase AprD4 and its partner reductase AprD3 in the C3'-deoxygenation of aminoglycoside antibiotics.** *J Antibiot (Tokyo)*. 2017; **70**(4): 423–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
41. Xie J, Talaska AE, Schacht J: **New developments in aminoglycoside therapy and ototoxicity.** *Hear Res*. 2011; **281**(1–2): 28–37.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
42. Fosso MY, Li Y, Garneau-Tsodikova S: **New trends in aminoglycosides use.** *Medchemcomm*. 2014; **5**(8): 1075–91.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
43. Ikeda H: **Natural products discovery from micro-organisms in the post-**

- genome era.** *Biosci Biotechnol Biochem.* 2017; **81**(1): 13–22.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
44. Armstrong ES, Miller GH: **Combating evolution with intelligent design: the neoglycoside ACHN-490.** *Curr Opin Microbiol.* 2010; **13**(5): 565–73.
[PubMed Abstract](#) | [Publisher Full Text](#)
45. Aggen JB, Armstrong ES, Goldblum AA, *et al.*: **Synthesis and spectrum of the neoglycoside ACHN-490.** *Antimicrob Agents Chemother.* 2010; **54**(11): 4636–42.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
46. Bassenden AV, Rodionov D, Shi K, *et al.*: **Structural Analysis of the Tobramycin and Gentamicin Clinical Resistome Reveals Limitations for Next-generation Aminoglycoside Design.** *ACS Chem Biol.* 2016; **11**(5): 1339–46.
[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review


Current Referee Status:  

Editorial Note on the Review Process

F1000 Faculty Reviews are commissioned from members of the prestigious F1000 Faculty and are edited as a service to readers. In order to make these reviews as comprehensive and accessible as possible, the referees provide input before publication and only the final, revised version is published. The referees who approved the final version are listed with their names and affiliations but without their reports on earlier versions (any comments will already have been addressed in the published version).

The referees who approved this article are:

Version 1

- 1 **Gong-Li Tang**  State Key Laboratory of Bioorganic and Natural Products Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, China
Competing Interests: No competing interests were disclosed.
- 2 **Albert M. Berghuis** Department of Biochemistry, McGill University, Montreal, Quebec, Canada
Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research